Monday, November 12, 2007

'Cruel injustice' of axed asbestos pay-outs

FAMILIES and campaigners yesterday condemned the "injustice" of a House of Lords ruling which will end compensation for thousands of workers suffering from an asbestos- related condition.

The judgment removes an established right to compensation, which had existed for 20 years, to allow people with pleural plaques - scars on the lungs - to claim damages.

Those affected claim these scars can develop into more serious conditions including cancer. However, their longstanding right to compensation was subject to an appeal by insurance companies, with the Court of Appeal finding in the companies' favour last year that pleural plaques was not a disease.

Unions appealed this and the controversial case went before the Lords yesterday, where the Court of Appeal decision was upheld.

The five Law Lords who heard the cases agreed that the appeals should be dismissed because the law does not offer compensation to victims of injuries which cause no or trivial damage.

Activists have now pledged to ask the Scottish Parliament to bring in new legislation in Scotland to reverse the Lords' judgment.

They have prepared a bill, which has cross-party support, and will submit it to Kenny MacAskill, the justice secretary, urging him to change the law north of the Border.

Harry McCluskey, secretary of Clydeside Action on Asbestos, which represents hundreds of families of former shipyard and factory workers, said: "The judgment has gone against the workers who have to live with the condition with the appalling fear that it could develop into mesothelioma [a form of cancer].

"It is a ridiculous judgment and the injustice is cruel."

Ian Tasker, of the STUC, said: "The STUC has supported asbestos groups and we are extremely disappointed that this is another injustice to the victims of asbestos.

"The legal system pays too much attention to business and it doesn't pay enough attention to the victims."

Pleural plaques can, over time, make breathing difficult and, in some cases, can be accompanied by the development of serious respiratory diseases including mesothelioma and lung cancer.

Previously, victims could claim between £6,000 to £10,000 if they had pleural plaques and more if they developed mesothelioma.

Bill Kidd, an SNP MSP and Robert Brown, a Liberal Democrat MSP, backed the move to introduce new legislation at the Scottish Parliament.

Mr Kidd said: "This decision by the House of Lords flies in the face of common sense and has to be rectified as quickly as possible."

Bill Butler, a Labour MSP, added: "[The ruling] comes down on the side of the employers and insurance companies and disregards the legitimate case of victims and their families."

Solicitor-advocate Frank Maguire, of Thompsons Solicitors, a leading campaigner for asbestos victims, said: "This judgment will only diminish respect for the law by showing how divorced it can be from reality."

SOURCE

Is Vitamin C a Viable Treatment for Cancer?

Vitamin C whether intravenous or oral is one of the most prevalent types of alternative and complimentary cancer therapies. Yet, this nutrient is still considered “controversial” by mainstream oncology. Since two time Nobel Prize winner (in chemistry and peace) Dr. Linus Pauling advocated its use in cancer starting in the late 1970’s, evidence to its efficacy has been quietly and steadily mounting.

Humans Do Not Make Vitamin C

Almost all animals and plants synthesize their own vitamin C except humans and a small number of other animals, including, apes, guinea pigs, the red-vented bulbul, a fruit-eating bat and a species of trout.

Vitamin C and Cancer - Early Work

Pure L-ascorbic acid (vitamin C) was first prepared in 1928 by the Nobel prize winning biochemist Albert Szent-Gyorgyi and in 1932 it was shown that this substance was vitamin C. In 1954 and 1959 Dr. W. J. McCormick, a Canadian physician, hypothesized that cancer is a collagen disease, secondary to a vitamin C deficiency. His theory was based on the fact that collagen is the “mortar” that binds cells together and if cells stick together, tumors would have a more difficult time breaking away and metastasizing. This concept was expanded upon when, in 1966, Dr. Ewan Cameron wrote a book entitled “Hyaluronidase and Cancer.” In it he pointed out that the ground substance or “intercellular cement” that binds cells of normal tissues contains various molecules that strengthen it including glycosaminoglycans and fibrils of collagen. Dr. Cameron discussed how tumors can produce enzymes that breakdown these molecules (i.e. hyaluronidase and collagenase).

Linus Pauling, Ph.D. (chemistry) had been interested in vitamin C for many years and had written previously how people required large amounts of vitamin C (1). Working with Dr. Cameron, Dr. Pauling pointed out that Vitamin C could: A) stimulate normal cells to produce increased amounts of a hyaluronidase inhibitor and; B) increase the number of collagen fibrils made (2). Based on these theories, Drs. Pauling and Cameron embarked on a number of studies to test the efficacy of vitamin C in cancer patients.

Pauling and Cameron Studies Find Improvement in Survival and Quality of Life

In 1976, Drs. Pauling and Cameron reported the survival times of 100 terminal cancer patients who were given supplemental ascorbate (10 grams/daily intravenously) and those of a control group of 1,000 patients of similar status treated by the same clinicians in the same hospital (Vale of Leven Hospital in Scotland) who had been managed identically except for the ascorbate. The 1,000 controls were matched by sex, age, primary tumor type, and clinical status. By August 10, 1976 all 1,000 of the controls had died while 18 of the 100 ascorbate-treated patients were still living. As of September 15, 1979, five ascorbate treated patients were still alive and “living normal lives.” The 100 acorbate-treated patients lived, on the average, 300 days longer than their matched controls with better quality of life (measured from the time all patients were considered “untreatable”).

A second study was performed in 1978 with 100 new ascorbate-treated patients and 1,000 matched controls (about half of the controls were in the original set) (3). This analysis broke out the improved survival times by cancer type. For each type of cancer there was an improvement in survival.

Mayo Clinic Studies Do Not Show Significant Benefit

Pauling’s and Cameron’s studies were not considered the gold standard in clinical studies. The gold standard was and remains the randomized, prospective, double-blind study in which half the patients are randomized to one arm of a study, half to another arm and neither the patient nor the doctor knows who is getting what.

To test whether ascorbate was effective, Dr. Charles Moertel and his colleagues at the Mayo Clinic conducted two randomized placebo controlled studies of patients each with advanced cancer (published in 1979 and 1985) (4). Patients randomized to the treatment group were given 10 grams of oral ascorbate, and neither study showed significant benefit. (In the first Mayo study, median survival was improved two weeks with the ascorbate group.) Because Moertel’s studies were taken as definitive, ascorbate treatment was considered useless. There were however, at least three significant differences between the Mayo Clinic’s “definitive” studies and those of Drs. Pauling and Cameron.

Mayo Clinic Studies Did Not Replicate the Studies by Pauling and Cameron

Difference #1 - In First Mayo Study Most Patients Were Pretreated With Chemo

The overwhelming majority - 87% (52 of 60 patients) of the patients in the first Mayo study had received chemotherapy before the study began. In contrast, only 4% of the patients in Pauling and Cameron study had received chemo. Pauling wrote, “It is known that cytotoxic chemotherapy damages the immune system and might prevent the vitamin C from being effective, inasmuch as it functions mainly by potentiating this system.(5)”

This is a valid critique. A Pubmed search for vitamin C reveals a large number of peer reviewed medical and scientific journal articles that demonstrate that vitamin C scavenges free radicals when it acts as an antioxidant (6), helps neutralize carcinogenic chemicals such as nitrosamine and nitrites (7), enhances lymphocyte function and mobilization of phagocytes (8), improves natural killer cell activities (9), modulates cell growth and differentiation (10), and enhances IgA, IgG and IgM antibody levels (11). Several of these mechanisms are directly related to the body’s immune system and to cancer resistance. Cytotoxic (cell-killing) chemotherapy is notorious for seriously compromising the patient’s immune system by killing the cells that mediate immunity. (Note: in the 1985 Mayo clinic study, this difference was removed as none of the Mayo patients were administered prior chemotherapy.)

Difference #2 - Pauling and Cameron Administered Intravenous Vitamin C, the Mayo Studies Used Only Oral Vitamin C

A commentary published by doctors from the National Institute of Health (NIH) in 2000 pointed out that there was a second significant difference in study design that may have accounted for the different results in the Mayo Clinic studies (12). The authors explained that intravenous (IV) administration (used by Pauling and Cameron) was superior to oral administration (used by Moertel) in respect to bioavailability of the vitamin. The NIH authors said, “It is now clear that intravenous administration of ascorbate can yield very high plasma levels, while oral treatment does not.” The NIH authors concluded that, “Moertel’s results were not comparable to those of Cameron, as ascorbate was given orally and not intravenously. In retrospect, the route of administration may have been key.”(13)

This observation was repeated in another peer reviewed paper published in 2004 in the Annals of Internal Medicine which stated “Because efficacy of vitamin C treatment cannot be judged from clinical trials that use only oral dosing, the role of vitamin C in cancer treatment should be reevaluated.” (14)

Difference #3 - In Pauling’s and Cameron’s Studies, Vitamin C Therapy Continued For the Life of the Patient

And yet a third difference with the Mayo Clinic study was that vitamin C administration was discontinued immediately after a patient could no longer take oral medications or there was progression of the disease. Apparently, in the Pauling and Cameron studies the IV doses continued regardless of the patient’s changing status. Vitamin C was provided during the life of the patient. However, in Moertel’s studies, because it was administered orally, vitamin C was discontinued in a large number of patients whenever there was a sign of worsening. According to writer Ralph Moss, “Because of the odd departure from Cameron’s protocol, patients in the treatment arm of the experiment (in Moertel’s second study) received vitamin C for a median time of only 10 weeks. None of the Mayo patients died while receiving it. Their deaths occurred after the vitamin had been taken away from them.”(15)

Was the Goal of the Mayo Studies to Replicate Pauling and Cameron’s Work or Denounce It?

Obviously if the Mayo Clinic studies were designed to test the outcomes of Drs. Pauling and Cameron studies then they should have replicated their methodology of administration (as long as it was scientifically reliable and clinically appropriate). Why didn’t Moertel’s group administer the vitamin intravenously throughout the life of the patient? We don’t know. Any one of these discrepancies described above should have been sufficient for a complete reevaluation, but as is so often the case, the cancer establishment had successfully “proved” that a mere vitamin was of no value in cancer and the case was closed. Or was it?

Vitamin C Therapy is Still Used Today

In the intervening 20 years since Moertel’s last study two trends have continued: 1) patients are being administered IV vitamin C in various cancer clinics around the world and many are showing benefit; 2) the overall plausibility of ascorbic acid administered intravenously as a cancer therapy is being better understood by recent insights into clinical pharmacokinetics and its in vitro cancer-specific cytotoxicity.

Clinical Examples from the National Cancer Institute

A reading of Drs. Cameron and Pauling’s book “Cancer and Vitamin C” provides 26 case histories of patients with various cancers who received a benefit from vitamin C including: brain, breast, prostate, bladder, lung, stomach, ovarian cancer, leukemia and mesothelioma. But, since Cameron and Pauling have been considered advocates of vitamin C, here is another more disinterested source. Three case examples come from a peer reviewed article whose authors come from the National Cancer Institute, the National Institutes of Health, and universities. In a March 2006 article entitled “Intravenously administered vitamin C as cancer therapy: three cases” the authors examined clinical details of three cases in accordance with National Cancer Institute (NCI) Best Case Series guidelines (16). Tumor pathology was verified by pathologists at the NCI who were unaware of diagnosis or treatment. In all three cases (metastatic renal cancer, bladder cancer, and lymphoma), vitamin C demonstrated efficacy.

Although these case histories by themselves are insufficient to prove that vitamin C is an effective treatment for cancer, in the words of these authors, these histories “increase the clinical plausibility of the notion that vitamin C administered intravenously might have effects on cancer under certain circumstances.(17)”

Biological Mechanisms of Vitmain C Are Better Understood Today

The number of peer reviewed journal articles continues to grow that describe the clinical pharmacokinetics and in vitro cancer-specific cytotoxicity of vitamin C. In other words, how Vitamin C is absorbed by the body and can kill cancer cells. For example, an article published in the Annals of Internal Medicine set out the pharmacokinetics of intravenous vitamin C (18); another article in the journal Nature discussed how vitamin C preferentially killed melanoma cells (19); and there have been several articles in Anticancer Research(20), and Oncology (21) that described how ascorbate killed various other cancer cell lines in vitro.

Vitamin C and Collagen

You may recall that Drs. Cameron and Pauling pointed out that Vitamin C could increase the number of collagen fibrils made. In the last 20 years biochemists have described the molecular basis of scurvy and in doing so have helped us understand how vitamin C and collagen are related. Apparently vitamin C plays a role in collagen metabolism by acting as a cofactor in the enzymatic reactions involved in the hydroxylation of praline and lysine. Without this hydroxylation, proper aligned stable helices of the alpha chains are not formed, so the procollagen that is formed is unstable and degraded (22).

Vitamin C May Prolong Life

Vitamin C has many roles that may be associated with fighting cancer including: acting as an anti-oxidant and scavenging free radicals, supporting the various immune cells, modulating cell growth and differentiation, helping to synthesize carnitine which is essential for the transport of fat to mitochondria, and possibly even strengthening collagen. The mounting evidence does suggest that Drs. Pauling and Cameron were right and that vitamin C is a benefit to cancer patients. We will conclude, therefore, with their words, “Vitamin C is not a miraculous cure for cancer, but…it significantly prolongs the life of the cancer patient…We believe that supplemental ascorbate can be of real help to all cancer patients and of quite dramatic benefit to a fortunate few.”(23)

Perhaps our health authorities will recognize the benefit of this “mere” vitamin. But, maybe the issue all along was not the fact that vitamin C is a potentially effective and non-toxic therapy, but rather that drug companies cannot make sufficient profits from it because as a vitamin it is difficult to patent. If this is the case, it would be an example of how economics not medicine decides what therapies are made available for cancer.

SOURCE

Monday, October 22, 2007

Rights of mesothelioma patients

Most of the mesothelioma patients are ignorant and innocent. They do not know about the rights of action available to them. Ignorance about their legal rights makes it easy for the evil industrialists to prosper, harm and escape.

Mesothelioma patients should first realize that mesothelioma is a preventable disease; it is caused exclusively due to exposure to asbestos fibers. The industrialists involved in the mining, manufacture and use of asbestos products was well aware of the harmful effects of asbestos. The short-term economic gains from asbestos made them blind to the long-term harmful effects from asbestos. Because of this, millions of people around the World suffered while these few amassed fortunes. They did nothing to protect the workers, their families and the society. In fact, they caused much harm by trying to conceal important research reports on the harmful effects of mesothelioma. They tried to bribe authorities and threatened researchers to safeguard their profitable positions. Therefore, mesothelioma patients worldwide have a right to file suit against these evil people to compensate them for their medical expenses, pain and suffering.

Legal Rights: The law gives the following rights to mesothelioma patients against these people who have caused them harm. Every mesothelioma patient has a right to be compensated for all his or her medical expenditure. They do not have to bear even any small part of it.

They have a right to be compensated for all the pain and suffering they have undergone. Most of the times, it is the negligence of the employer or industry that has resulted in the person contracting mesothelioma. Even if you have very little time left on earth, you can opt for a huge compensation to enjoy that little life left or to safeguard the financial situation of your dependents. Immediate action is necessary in case of a mesothelioma diagnosis. File your case immediately using expert legal help. Mostly, mesothelioma lawyers do not charge any fees if they have not won any settlement for you. If they win a settlement, they usually charge a percentage of the settlement as their fees. Make all your paperwork ready before the case appears in court. Provide it to your lawyer and brief him in as detailed manner as possible. The data has to be very comprehensive and in depth. So, start early in compiling it.

There may be a situation in which you have no idea about how you contracted the disease. In this case, it is best to consult your lawyer who may be able to guide you in this matter. With his guidance, you can spot the factor that contributed to your contracting this disease. Then, you can proceed in the above stated manner. You have a duty towards your family and dependents and mesothelioma makes you feel guilty that you are unable to perform your duty. The settlement that you win out of your case will help in your children' education and in your spouses old age. So, file your case as soon as you are diagnosed with mesothelioma. The settlement will help your soul rest in peace.


About the Author
Archana Sarat ia a freelance writer and research expert at a medical research firm. to know more about mesothelioma log on to http://www.rarehope.com

Friday, September 28, 2007

Veterans Suffering From Asbestos-Related Disease

According to statistics, more than 30% of Americans suffering from mesothelioma--a deadly asbestos-induced lung cancer--were exposed to asbestos while serving their country. Veterans and shipyard workers face the greatest risk of developing mesothelioma or similar diseases because of the extensive use of asbestos in military equipment and products, buildings, ships, and submarines. This is especially true for veterans who served during or after World War II and before the1970s when the government began regulating use of asbestos.

Sadly, hundreds of thousands, if not millions, of American veterans have suffered exposure to asbestos, putting them at higher risk of developing asbestosis, mesothelioma, or other illness.

Veterans who have been diagnosed with an asbestos-induced lung cancer such as mesothelioma have legal rights and may be able to recover compensation for their losses and suffering. Only an experienced mesothelioma lawyer will know if you have a valid legal claim.

Navy Veterans at Risk

Asbestos-induced lung cancer is a significant problem among Navy veterans, particularly because the use of asbestos was so very extensive on ships. Virtually no area on a Navy ship built before the 1970s is safe including: · Fire and engine rooms
· Boiler rooms
· Navigation rooms
· Mess halls
· Sleeping quarters Additionally, commonly used products such as gaskets, cables, insulation, adhesives, valves, and numerous others contained asbestos. Navy veterans, like other veterans, were prone to carry asbestos dust home on their clothes, thereby exposing their loved ones to the dangerous fibers.

Rights of Veterans

Veterans groups across the country have started taking action to ensure their rights are protected. For instance, some veterans organizations have called on Congress to fund early lung cancer detection programs, which is especially important given the long latency period for mesothelioma--usually 30 to 50 years. Individual veterans, and, in some cases, their families, are filing legal claims to hold responsible parties accountable for the suffering caused by asbestos-induced lung disease.

About the Author
If you or a loved one is a veteran who has been diagnosed with asbestos-related disease or illness, please contact an experienced Chicago Workers Compensation Lawyer at the Law Offices of Barry G. Doyle, P.C., serving residents of Chicago, Rockford, Aurora, and surrounding areas of Illinois.

Saturday, September 8, 2007

lawsuit asbestos lawyer

The number of asbestos lawsuits filed and the number of asbestos lawsuit lawyers who will take up an asbestos lawsuit case are a sad reflection of a long-time construction mistake that may lead to the ill health of over 250,000 Americans by the year 2020. If you think you may have been exposed to asbestos without proper protective filter masks, you may be entitled to file a lawsuit with the help of an asbestos lawyer.

A natural, fibrous form of a number of minerals, asbestos was used since ancient times in fabrics because of its durability and fireproofing ability. For over seventy years, asbestos was used in the insulation of and as fireproofing material in numerous buildings. Over 30 millions tons of asbestos in America alone made its way into the walls of commercial buildings, home, schools, shipyards, and industrial sites. Construction workers labored with asbestos without protection.

In the 1970s, however, the medical community, faced with an overwhelming number of construction workers coming down with illnesses, found that inhaling asbestos can lead to mesothelioma, a form of lung cancer, and the material was immediately banned for use in construction. Over the years, scientists have also linked asbestos to pleural disease, gastrointestinal cancer, and a disease specifically diagnosed for asbestos exposure, asbestosis.

A lawyer who specializes in asbestos lawsuits can tell you that each year asbestos surfaces in over 3000 new people and 10,000 people die of asbestos-related disease. As asbestos can line the lungs and accumulate over long periods of years before the body exhibits any symptoms, even workers who haven't worked in the construction field for twenty to fifty years have come down with asbestos-related diseases.

Asbestos lawsuit lawyers have filed lawsuits for more than just construction workers, though. Even some family members of construction workers have exhibited some form of asbestos disease because asbestos fibers can travel on clothing. Buildings over thirty years old that were made with asbestos likewise can seep asbestos to its occupants over time, although some efforts have been made to correct those buildings.

Do you think that you have been exposed to asbestos at a work site or by living in an asbestos-filled building or with a worker who was exposed to asbestos? You may be able to file a lawsuit, so contact an asbestos lawsuit lawyer. Some asbestos lawsuit lawyers have gotten their clients as much as $7.5 million dollars to offset the medical bills, pain, and suffering that have resulted as a consequence of this massive construction oversight.

If you feel that you may have been contaminated by asbestos, don't hesitate to see a doctor. If you find that you have suffered from asbestos complications, consult an asbestos lawsuit lawyer to decide where you should go from there. For one asbestos lawsuit firm that gives good information about asbestos contamination sites in the US and offers a free asbestos lawyer case evaluation, visit abestoslawsuitinfo.com.

About the Author
frank j vanderlugt owns and operates http://www.lawsuit-abestos-lawyer-abcmesotheolioma.info 2 Lawsuitabestoslawyerabcmesotheoliomainfo

Wednesday, August 22, 2007

Docetaxel for Malignant Mesothelioma

Docetaxel has activity in a wide variety of solid tumors. To evaluate its efficacy in malignant mesothelioma, previously untreated patients (pts.) were treated with docetaxel 100 mg/m[Superscript 2], 1-hour infusion administered every 21 days.
Dexamethasone 8 mg twice daily was also administered for five days starting 24 hours prior to docetaxel infusion. A total of 20 pts. Were accrued to the first stage of the study between December 1996 and April 1997. Nineteen of the 20 pts. Had histological confirmation of mesothelioma and the tumors were carcinoembryonic antigen and mucin negative. In one patient (pt.) the histology could not be confirmed and he was considered ineligible. Characteristics of the remaining 19 pts. Include: 5% ECOG Performance Status (PS) 0; 68% PS 1; 26% PS 2; median age 69 years (range 57--81); 89% male. Only one pt. Had a partial response, with an overall response rate of 5% (95% CI 0.16--26.4). Three pts. (16%) had stable disease, 11 (58%) progressed on treatment and 4 (21%) were not evaluable for response. One pt. With stable disease has not relapsed so far after 16 months of follow-up.
There were three deaths during the treatment phase: One died of gastrointestinal hemorrhage, one from rapidly progressive disease with brain metastasis and one definite treatment related septic death with multi-organ failure.

The major toxicity seen was myelosuppression with grade 4 leucopenia in 17 pts. (90%) and grade 4 granulocytopenia in 8 (42%) pts. Other rare grade 4 non-hematologic toxicities included: Vomiting (1 pt.), diarrhea (1 pt.), hypersensitivity reaction (1 pt.) and cardiac toxicity (1 pt.). The study was terminated after the first accrual stage due to insufficient responses. In conclusion: Docetaxel is not an effective agent in malignant mesothelioma and does not warrant further investigation. (Conducted by ECOG and supported in part by PHS grants CA18653, CA23318, CA52743, CA13650, CA49957, CA66636, CA21115 from the NCI, NIH and the DHHS.)

Thursday, August 2, 2007

Chemotherapy in malignant pleural mesothelioma

We reviewed the published literature of clinical studies in malignant pleural mesothelioma, including phase II trials of the newer antifolates and plant derivatives, as well as older single- agent and combination chemotherapy trials. We excluded trials with less than 15 patients, although we have mentioned smaller trials in the text to make a specific point, as well as ones that show promise. We have also included confidence intervals when cited in the original reports, or calculated them when absent.

No drugs have consistently induced a response greater than 20%. Higher response rates have been reported with detorubicin, high-dose methotrexate, and edatrexate at 26%, 37%, and 25%, respectively, but these have yet to be confirmed. Agents that produce response rates in 10% to 20% of patients include doxorubicin, epirubicin, mitomycin, cyclophosphamide, ifosfamide, cisplatin, and carboplatin. Combination chemotherapy trials do not demonstrate a consistently greater response rate than single-agent trials. However, the combination of doxorubicin, cisplatin, bleomycin, and mitomycin demonstrated a response rate of 44% (95% confidence interval, 27% to 63%), but this remains unconfirmed. Intrapleural therapy using interferon gamma, particularly for small-volume disease, shows promise.

The successful treatment of unresectable pleural mesothelioma awaits the discovery of active drugs. Recent trials of high-dose methotrexate and other antifolates are encouraging. Newer agents, including suramin, should be evaluated in phase II trials. Off-protocol combination therapy cannot be recommended over single-agent therapy, but studies that use combinations of the newer agents should be conducted.

LinkWithin